A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular targets of SARS-CoV-2 (preprint)

The SARS-CoV-2 pandemic has caused over 1 million deaths globally, mostly due to acute lung injury and acute respiratory distress syndrome, or direct complications resulting in multiple-organ failures. Little is known about the host tissue immune and cellular responses associated with COVID-19 infection, symptoms, and lethality. To address this, we collected tissues from 11 organs during the clinical autopsy of 17 individuals who succumbed to COVID-19, resulting in a tissue bank of approximately 420 specimens. We generated comprehensive cellular maps capturing COVID-19 biology related to patients demise through single-cell and single-nucleus RNA-Seq of lung, kidney, liver and heart tissues, and further contextualized our findings through spatial RNA profiling of distinct lung regions. We developed a computational framework that incorporates removal of ambient RNA and automated cell type annotation to facilitate comparison with other healthy and diseased tissue atlases. In the lung, we uncovered significantly altered transcriptional programs within the epithelial, immune, and stromal compartments and cell intrinsic changes in multiple cell types relative to lung tissue from healthy controls. We observed evidence of: alveolar type 2 (AT2) differentiation replacing depleted alveolar type 1 (AT1) lung epithelial cells, as previously seen in fibrosis; a concomitant increase in myofibroblasts reflective of defective tissue repair; and, putative TP63+ intrapulmonary basal-like progenitor (IPBLP) cells, similar to cells identified in H1N1 influenza, that may serve as an emergency cellular reserve for severely damaged alveoli. Together, these findings suggest the activation and failure of multiple avenues for regeneration of the epithelium in these terminal lungs. SARS-CoV-2 RNA reads were enriched in lung mononuclear phagocytic cells and endothelial cells, and these cells expressed distinct host response transcriptional programs. We corroborated the compositional and transcriptional changes in lung tissue through spatial analysis of RNA profiles in situ and distinguished unique tissue host responses between regions with and without viral RNA, and in COVID-19 donor tissues relative to healthy lung. Finally, we analyzed genetic regions implicated in COVID-19 GWAS with transcriptomic data to implicate specific cell types and genes associated with disease severity. Overall, our COVID-19 cell atlas is a foundational dataset to better understand the biological impact of SARS-CoV-2 infection across the human body and empowers the identification of new therapeutic interventions and prevention strategies.

Regenerative intermediates could be culprits in lung scarring (preprint)

Our lungs use very fine tissues to exchange oxygen and carbon dioxide between the air and our blood. About 95% of this tissue is made up of a single kind of cell, called type-1 pneumocytes, or AT1 cells. Because they’re so delicate and thin, these cells are vulnerable to damage by pollutants, viruses, and bacteria. Fortunately, lung tissues also have specialized stem cells called AT2 cells that can replace damaged AT1 cells. But exactly how these cube-shaped AT2 cells generate large, flat AT1 cells has remained something of a mystery. To study this problem, the Tata lab in Cell Biology at Duke University has created “mini lungs” inside Petri dishes. They found that inside these “organoids”, the blocky stem cells enter an intermediate state on their way to generating the thin AT1 cells. The stem cells stretch considerably while passing through this transitional state, making them vulnerable to DNA damage. Cells normally pass through that transition within days. But under certain conditions, stem cells can become locked in the transition state, leading to lung scarring. Once the researchers knew what to look for, they found increasing numbers of transitional cells in scarred human lungs. This kind of damage can be seen when any number of harmful factors take hold of the lung, including toxins and infectious diseases, like COVID-19. Though more research is needed, the researchers believe that this intermediate state of stem cells is key to healing from COVID-19 to prevent scarring.

SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2 (preprint)

Antiviral therapeutics against SARS-CoV-2 are needed to treat the pandemic disease COVID-19. Pharmacological targeting of a host factor required for viral replication can suppress viral spread with a low probability of viral mutation leading to resistance. Here, we used a genome-wide loss of function CRISPR/Cas9 screen in human lung epithelial cells to identify potential host therapeutic targets. Validation of our screening hits revealed that the kinase SRPK1, together with the closely related SRPK2, were jointly essential for SARS-CoV-2 replication; inhibition of SRPK1/2 with small molecules led to a dramatic decrease (more than 100,000-fold) in SARS-CoV-2 virus production in immortalized and primary human lung cells. Subsequent biochemical studies revealed that SPRK1/2 phosphorylate the viral nucleocapsid (N) protein at sites highly conserved across human coronaviruses and, due to this conservation, even a distantly related coronavirus was highly sensitive to an SPRK1/2 inhibitor. Together, these data suggest that SRPK1/2-targeted therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.